About This Trial
Intravenously administered mRNA encoding a secreted antibody targeting Claudin 18.2.
Primary Endpoints
- Safety
- Antibody expression levels
- Tumor response
Latest Update
January 2026
Dose escalation ongoing. Therapeutic antibody levels detected in all patients at higher dose levels.